Eton Pharmaceuticals (ETON) Common Equity (2017 - 2025)

Eton Pharmaceuticals (ETON) has 9 years of Common Equity data on file, last reported at $26.2 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 7.07% year-over-year to $26.2 million; the trailing twelve-month figure through Dec 2025 stood at $26.2 million (up 7.07% YoY), and the FY2025 full-year result was $26.2 million, up 7.07% from the prior year.
• Common Equity advanced to $26.2 million in Q4 2025, from $23.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $26.2 million in Q4 2025 to a low of $11.2 million in Q3 2022.
• A 5-year average of $17.7 million and a median of $16.4 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 1028.24% in 2021 and sank 37.91% in 2022, its largest moves.
• Tracing ETON's Common Equity over 5 years: stood at $17.6 million in 2021, then fell by 25.82% to $13.1 million in 2022, then increased by 18.34% to $15.5 million in 2023, then surged by 57.83% to $24.4 million in 2024, then advanced by 7.07% to $26.2 million in 2025.
• Business Quant data shows ETON's Common Equity at $26.2 million in Q4 2025, $23.1 million in Q3 2025, and $24.0 million in Q2 2025.